ECSP109879A - Compuestos y metodos para modular el receptor - Google Patents
Compuestos y metodos para modular el receptorInfo
- Publication number
- ECSP109879A ECSP109879A EC2010009879A ECSP109879A ECSP109879A EC SP109879 A ECSP109879 A EC SP109879A EC 2010009879 A EC2010009879 A EC 2010009879A EC SP109879 A ECSP109879 A EC SP109879A EC SP109879 A ECSP109879 A EC SP109879A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- methods
- modulate
- receiver
- dyslipidemia
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 2
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94997407P | 2007-07-16 | 2007-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP109879A true ECSP109879A (es) | 2010-02-26 |
Family
ID=39855171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010009879A ECSP109879A (es) | 2007-07-16 | 2010-01-15 | Compuestos y metodos para modular el receptor |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8153624B2 (enExample) |
| EP (1) | EP2178851B1 (enExample) |
| JP (1) | JP5373788B2 (enExample) |
| KR (1) | KR101157334B1 (enExample) |
| CN (1) | CN101743232B (enExample) |
| AR (1) | AR067540A1 (enExample) |
| AT (1) | ATE539065T1 (enExample) |
| AU (1) | AU2008276236B2 (enExample) |
| BR (1) | BRPI0814571A2 (enExample) |
| CA (1) | CA2693406C (enExample) |
| CL (1) | CL2008002051A1 (enExample) |
| CO (1) | CO6270212A2 (enExample) |
| CY (1) | CY1112298T1 (enExample) |
| DK (1) | DK2178851T3 (enExample) |
| DO (1) | DOP2010000018A (enExample) |
| EA (1) | EA016475B1 (enExample) |
| EC (1) | ECSP109879A (enExample) |
| ES (1) | ES2376176T3 (enExample) |
| HR (1) | HRP20120048T1 (enExample) |
| IL (1) | IL202234A0 (enExample) |
| MA (1) | MA31683B1 (enExample) |
| MX (1) | MX2010000502A (enExample) |
| PE (1) | PE20090809A1 (enExample) |
| PL (1) | PL2178851T3 (enExample) |
| PT (1) | PT2178851E (enExample) |
| RS (1) | RS52216B (enExample) |
| SI (1) | SI2178851T1 (enExample) |
| SV (1) | SV2010003458A (enExample) |
| TN (1) | TN2010000028A1 (enExample) |
| TW (1) | TW200906823A (enExample) |
| WO (1) | WO2009012125A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP2014500319A (ja) * | 2010-12-20 | 2014-01-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ファルネソイドｘ受容体を調節するための組成物および方法 |
| WO2012087520A1 (en) * | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| EP2970177A1 (en) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
| SI3043865T1 (sl) | 2013-09-11 | 2021-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B |
| KR102350357B1 (ko) * | 2013-11-05 | 2022-01-14 | 노파르티스 아게 | 파르네소이드 x 수용체의 조정을 위한 조성물 및 방법 |
| CN104045635A (zh) * | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3034501A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EP3034499A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| EA036404B1 (ru) | 2015-02-06 | 2020-11-06 | Интерсепт Фармасьютикалз, Инк. | Фармацевтические композиции для комбинированной терапии |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| CA2981503C (en) | 2015-03-31 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CR20170456A (es) | 2015-04-07 | 2018-06-13 | Intercept Pharmaceuticals Inc | Composiciones farmacéuticas para terapias combinadas |
| CN106946867B (zh) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| CN107021958A (zh) * | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| US11419878B2 (en) | 2016-03-28 | 2022-08-23 | Intercept Pharmaceuticals, Inc. | Medicine obtained by combining FXR agonist and ARB |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189651A1 (en) * | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| MA55632A (fr) * | 2016-08-23 | 2022-02-16 | Ardelyx Inc | Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques |
| US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
| RU2019110779A (ru) * | 2016-09-14 | 2020-10-15 | Новартис Аг | Новые схемы введения агонистов fxr |
| MX2019003790A (es) * | 2016-10-04 | 2019-09-26 | Enanta Pharm Inc | Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos. |
| WO2018081285A1 (en) | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
| SI4122464T1 (sl) | 2017-03-28 | 2024-07-31 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| MX394743B (es) * | 2017-04-12 | 2025-03-04 | Il Dong Pharma | Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos |
| CN109265471B (zh) * | 2017-06-30 | 2021-06-04 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| CN109320509B (zh) * | 2017-07-31 | 2022-02-08 | 轩竹生物科技股份有限公司 | Fxr受体激动剂 |
| JP7271513B2 (ja) | 2017-09-14 | 2023-05-11 | アルデリックス， インコーポレイテッド | 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬 |
| CN111278817B (zh) | 2017-11-01 | 2023-05-16 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的多环化合物 |
| JP7264906B2 (ja) * | 2017-11-01 | 2023-04-25 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物 |
| CA3081424A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Spirocyclic compounds as farnesoid x receptor modulators |
| CN111630051B (zh) | 2017-11-01 | 2023-12-26 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的烯烃螺环化合物 |
| PE20201170A1 (es) | 2017-11-01 | 2020-10-28 | Bristol Myers Squibb Co | Compuestos biciclicos en puente como moduladores del receptor farnesoide x |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US11667629B2 (en) | 2017-12-22 | 2023-06-06 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Isoxazole derivative, preparation method therefor, and use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CN110452235B (zh) * | 2018-05-08 | 2023-02-17 | 中国科学院上海药物研究所 | 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途 |
| EP3844156A4 (en) * | 2018-08-30 | 2022-06-08 | Terns Pharmaceuticals, Inc. | TREATMENT OF HEPATIC DISORDERS |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| PT3911647T (pt) | 2019-01-15 | 2024-03-04 | Gilead Sciences Inc | Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| CN113677659B (zh) | 2019-02-15 | 2024-09-06 | 百时美施贵宝公司 | 可用作类法尼醇x受体调节剂的经取代的酰胺化合物 |
| KR20210129684A (ko) | 2019-02-15 | 2021-10-28 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서 유용한 치환된 아미드 화합물 |
| CN113677666A (zh) | 2019-02-15 | 2021-11-19 | 百时美施贵宝公司 | 作为类法尼醇x受体调节剂的经取代的双环化合物 |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| KR20250076664A (ko) | 2019-04-19 | 2025-05-29 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | Fxr 소분자 작용제 및 이의 제조 방법과 용도 |
| WO2020231917A1 (en) * | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| SG11202113155XA (en) | 2019-05-30 | 2021-12-30 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
| EP3999101A1 (en) | 2019-07-18 | 2022-05-25 | ENYO Pharma | Method for decreasing adverse-effects of interferon |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| KR20220098168A (ko) * | 2019-11-08 | 2022-07-11 | 테른스 파마슈티칼스, 인크. | 간 장애의 치료 |
| WO2021108974A1 (en) | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| US20210379043A1 (en) * | 2020-05-13 | 2021-12-09 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| CA3193057A1 (en) | 2020-08-25 | 2022-03-03 | Eli Lilly And Company | Polymorphs of an ssao inhibitor |
| EP4210705A4 (en) * | 2020-09-11 | 2024-11-13 | Terns Pharmaceuticals, Inc. | SOLID DISPERSION FORMULATIONS OF A FXR AGONIST |
| AU2021359895A1 (en) * | 2020-10-15 | 2023-06-15 | Eli Lilly And Company | Polymorphs of an fxr agonist |
| KR20230154806A (ko) | 2021-01-14 | 2023-11-09 | 엔요 파마 | Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과 |
| CN117320722A (zh) | 2021-04-28 | 2023-12-29 | 埃尼奥制药公司 | 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用 |
| CN119013027A (zh) | 2021-11-11 | 2024-11-22 | 拓臻制药公司 | 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合 |
| WO2023220404A1 (en) * | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
| CN115850152B (zh) * | 2022-12-20 | 2025-10-31 | 河北鼎泰制药有限公司 | 一种杂质A-7-imp3的制备方法及其用途 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138258A (ja) * | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
| JP2002532729A (ja) | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
| US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| US6967212B2 (en) * | 2001-05-30 | 2005-11-22 | Bristol-Myers Squibb Company | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| BR0312503A (pt) | 2002-07-09 | 2007-06-26 | Bristol Myers Squibb Co | derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos |
| JP2006515838A (ja) * | 2002-11-22 | 2006-06-08 | スミスクライン ビーチャム コーポレーション | ファルネソイドｘ受容体アゴニスト |
| CA2640476A1 (en) | 2006-02-03 | 2007-08-16 | Eli Lilly And Company | Compounds and methods for modulating fx-receptors |
| BRPI0712262A2 (pt) | 2006-05-24 | 2012-07-10 | Lilly Co Eli | agonistas de fxr |
| US8106077B2 (en) | 2006-05-24 | 2012-01-31 | Eli Lilly And Company | Compounds and methods for modulating FXR |
-
2008
- 2008-07-03 TW TW097125064A patent/TW200906823A/zh unknown
- 2008-07-11 JP JP2010517082A patent/JP5373788B2/ja active Active
- 2008-07-11 HR HR20120048T patent/HRP20120048T1/hr unknown
- 2008-07-11 AU AU2008276236A patent/AU2008276236B2/en not_active Ceased
- 2008-07-11 CN CN2008800247651A patent/CN101743232B/zh active Active
- 2008-07-11 ES ES08781651T patent/ES2376176T3/es active Active
- 2008-07-11 MX MX2010000502A patent/MX2010000502A/es active IP Right Grant
- 2008-07-11 AT AT08781651T patent/ATE539065T1/de active
- 2008-07-11 BR BRPI0814571-7A2A patent/BRPI0814571A2/pt not_active IP Right Cessation
- 2008-07-11 PE PE2008001168A patent/PE20090809A1/es not_active Application Discontinuation
- 2008-07-11 EA EA201070148A patent/EA016475B1/ru not_active IP Right Cessation
- 2008-07-11 US US12/600,879 patent/US8153624B2/en active Active
- 2008-07-11 EP EP08781651A patent/EP2178851B1/en active Active
- 2008-07-11 PT PT08781651T patent/PT2178851E/pt unknown
- 2008-07-11 DK DK08781651.8T patent/DK2178851T3/da active
- 2008-07-11 CA CA2693406A patent/CA2693406C/en not_active Expired - Fee Related
- 2008-07-11 RS RS20120099A patent/RS52216B/sr unknown
- 2008-07-11 PL PL08781651T patent/PL2178851T3/pl unknown
- 2008-07-11 WO PCT/US2008/069719 patent/WO2009012125A1/en not_active Ceased
- 2008-07-11 KR KR1020107000896A patent/KR101157334B1/ko not_active Expired - Fee Related
- 2008-07-11 SI SI200830514T patent/SI2178851T1/sl unknown
- 2008-07-14 AR ARP080103026A patent/AR067540A1/es not_active Application Discontinuation
- 2008-07-14 CL CL2008002051A patent/CL2008002051A1/es unknown
-
2009
- 2009-11-19 IL IL202234A patent/IL202234A0/en unknown
-
2010
- 2010-01-12 CO CO10002335A patent/CO6270212A2/es not_active Application Discontinuation
- 2010-01-12 DO DO2010000018A patent/DOP2010000018A/es unknown
- 2010-01-15 TN TNP2010000028A patent/TN2010000028A1/fr unknown
- 2010-01-15 EC EC2010009879A patent/ECSP109879A/es unknown
- 2010-01-15 SV SV2010003458A patent/SV2010003458A/es not_active Application Discontinuation
- 2010-02-11 MA MA32615A patent/MA31683B1/fr unknown
-
2012
- 2012-01-27 CY CY20121100098T patent/CY1112298T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP109879A (es) | Compuestos y metodos para modular el receptor | |
| UY32863A (es) | COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR | |
| UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| UY32859A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| PA8819201A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| NI201000119A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis. | |
| UY32916A (es) | Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones | |
| CO6331340A2 (es) | Pirrolo-pirimidinas y pirrolo piridinas | |
| CR11373A (es) | COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA | |
| EA200870570A1 (ru) | Агонисты fxr | |
| ECSP10010599A (es) | Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk) | |
| MX388468B (es) | Compuestos multicíclicos y métodos de uso de los mismos. | |
| CR20120510A (es) | Derivados de piperidin-4-il azetidina como inhibidores de jak1 | |
| ECSP12011622A (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
| GT201400290A (es) | Carboxamidas heterociclicas fungicidas | |
| UY39338A (es) | Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos | |
| ECSP12012065A (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos | |
| UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
| CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
| PA8842101A1 (es) | Heteroarilos sustituidos | |
| CR10060A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| CO6470820A2 (es) | Espiro-epóxidos como productos intermedios | |
| UY30916A1 (es) | Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros | |
| UY30729A1 (es) | Derivados de pirrol, su preparacion y su utilizacion en terapéutica | |
| CU20100073A7 (es) | Nuevos derivados no peptídicos como antagonistas b1 de la bradiquinina |